Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.J Clin Oncol. 2008; 26: 814-819
- Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer.J Clin Oncol. 2020; 38: 4184-4193
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).J Clin Oncol. 2015; 33: 13-21
- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.Ann Oncol. 2022; 33: 384-394
- Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.JAMA. 2013; 310: 1455-1461
- Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.Lancet Oncol. 2013; 14: 609-618
- Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.J Clin Oncol. 2015; 33: 258-264
- Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol. 2012; 30: 1796-1804
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet. 2014; 384 (Epub 2014 Feb 14. Erratum in: Lancet. 2019 Mar 9;393(10175):986): 164-172https://doi.org/10.1016/S0140-6736(13)62422-8
- Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol. 2007; 25: 4414-4422
- Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.J Clin Oncol. 2017; 35: 1049-1060
- Practical Approach to Triple-Negative Breast Cancer.J Oncol Pract. 2017; 13: 293-300
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest. 2011; 121: 2750-2767
- Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Clin Cancer Res. 2015; 21: 1688-1698
- Defining breast cancer intrinsic subtypes by quantitative receptor expression.Oncologist. 2015; 20: 474-482
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet. 2012; 379: 432-444
- Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).J Clin Oncol. 2017; 35: 2647-2655
- The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.Breast Cancer Res Treat. 2013; 138: 783-794
- CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.J Clin Oncol. 2022; 40: 1323-1334
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Lancet Oncol. 2014; 15: 747-756
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.Ann Oncol. 2018; 29: 2341-2347
- Cancer immunotherapy: the beginning of the end of cancer?.BMC Med. 2016; 14: 73
- Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.JAMA Oncol. 2020; 6: 676-684
- KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020; 382: 810-821
- KEYNOTE-522 investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.N Engl J Med. 2022; 386: 556-567
- NCCN Clinical practice guidelines in oncology. Breast cancer version 4.2022.(Accessed August 15, 2022)
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.N Engl J Med. 2017; 376: 2147-2159
- Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.J Clin Oncol. 2012; 30: 11-18
- Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.Clin Cancer Res. 2015; 21: 4305-4311
- Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials.Eur J Cancer. 2017; 77: 40-47
- OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med. 2021; 384: 2394-2405
- Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science. 1989; 244: 707-712
- Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline.J Clin Oncol. 2021; 39: 1485-1505
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.J Clin Oncol. 2014; 32: 3744-3752
- APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.N Engl J Med. 2017; 377: 122-131
- APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.J Clin Oncol. 2021; 39: 1448-1457
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet. 2010; 375: 377-384
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.Lancet Oncol. 2012; 13: 25-32
- Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.ESMO Open. 2022; 7: 100433
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2016; 17: 367-377
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol. 2018; 19: 115-126
Metzger Filho O, Viale G, Trippa L, et al: HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. 2019 ASCO Annual Meeting. Abstract 502. Presented June 3, 2019.
- Adjuvant trastuzumab in HER2-positive breast cancer.N Engl J Med. 2011; 365: 1273-1283
- Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 1630-1640
- Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial.JAMA Oncol. 2021; 7: 978-984
- KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med. 2019; 380: 617-628
- Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis.JAMA Oncol. 2016; 2: 1477-1486
- Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.Clin Cancer Res. 2004; 10: 6622-6628
- Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.Ann Oncol. 2008; 19: 465-472
- Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.Cancer. 2006; 106: 2095-2103
- Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.J Clin Oncol. 2005; 23: 5108-5116
- Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.Br J Cancer. 2010; 103: 759-764
- The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.Chin Clin Oncol. 2015; 4: 34
- Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the american college of surgeons oncology group Z1031 trial (Alliance).J Clin Oncol. 2017; 35: 1061-1069
- Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Pharmgenomics Pers Med. 2014; 7: 203-215
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol. 2020; 38: 3987-3998
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.Clin Cancer Res. 2020; 26: 566-580
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.J Clin Oncol. 2019; 37: 178-189
- Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst. 2008; 100: 1380-1388
- Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).J Clin Oncol. 2020; 38: 505
- SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med. 2019; 380: 1929-1940
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol. 2019; 20: 1226-1238
- Circulating Tumor DNA in HER2-Amplified Breast Cancer: a translational research substudy of the NeoALTTO Phase III Trial.Clin Cancer Res. 2019; 25: 3581-3588
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Ann Oncol. 2021; 32: 229-239
- Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).J Clin Oncol. 2022; 40: abstr 103
Wolf DM, Yau C, Brown-Swigart L, Hirst G, Buxton M, Paoloni M, I-SPY2 TRIAL Investigators, Olopade O, DeMichele A, Symmans F, Rugo H, Berry D, Esserman L, van t Veer L. Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer [Abstract]. In: AACR 107th Annual Meeting 2016 April 16-20, Abstract nr 859.
- Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.JCO Precis Oncol. 2022; 6: e2100463
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol. 2018; 19: 40-50
Article info
Publication history
Published online: October 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
